INMB (STOCKS)
INmune Bio Inc. Common stock
$1.251700
+0.071700 (+6.08%)
Prev close: $1.180000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- David J. Moss
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $33.50M
- Employees
- 13
- P/E (TTM)
- -0.64
- P/B (TTM)
- 1.33
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.20 | $-0.27 | +0.0652 | +24.59% |
|
Sep 2025 (Q3)
|
$-0.24 | $-0.33 | +0.0915 | +27.60% |
|
Jun 2025 (Q2)
|
$-1.05 | $-0.39 | -0.6607 | -169.71% |
|
Mar 2025 (Q1)
|
$-0.43 | $-0.48 | +0.0494 | +10.30% |
Financial Statements
| Revenues | $50.00K |
| Benefits Costs and Expenses | -$45.88M |
| Costs And Expenses | -$45.88M |
| Nonoperating Income/Loss | $1.45M |
| Operating Expenses | $47.43M |
| Research and Development | $20.66M |
| Other Operating Expenses | $26.77M |
| Operating Income/Loss | -$47.38M |
| Income/Loss From Continuing Operations After Tax | $45.93M |
| Income/Loss From Continuing Operations Before Tax | $45.93M |
| Net Income/Loss | -$45.93M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$45.93M |
| Net Income/Loss Available To Common Stockholders, Basic | -$45.93M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.86 |
| Diluted Earnings Per Share | -$1.86 |
| Basic Average Shares | 24,757,545 |
| Diluted Average Shares | 24,757,545 |
| Assets | $32.35M |
| Current Assets | $29.89M |
| Noncurrent Assets | $2.46M |
| Liabilities | $8.83M |
| Current Liabilities | $8.42M |
| Noncurrent Liabilities | $411.00K |
| Equity | $23.52M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $23.52M |
| Liabilities And Equity | $32.35M |
| Net Cash Flow From Operating Activities | -$22.58M |
| Net Cash Flow From Operating Activities, Continuing | -$22.58M |
| Net Cash Flow From Investing Activities | -$4.87M |
| Net Cash Flow From Investing Activities, Continuing | -$5.03M |
| Net Cash Flow From Financing Activities | $27.61M |
| Net Cash Flow From Financing Activities, Continuing | $27.61M |
| Exchange Gains/Losses | -$159.00K |
| Net Cash Flow | $159.00K |
| Net Cash Flow, Continuing | $318.00K |
| Comprehensive Income/Loss | -$46.10M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$46.10M |
| Other Comprehensive Income/Loss | -$46.10M |